NCT00954304

Duration of P-glycoprotein Inhibition After Oral Administration of HM30181AK Tablet

Clinical Trial to Investigate the Duration of P-glycoprotein Inhibition After Oral Administration of HM30181AK Tablet in Healthy Male Subjects : An Open, Parallel Dose Group Design

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Hanmi Pharmaceutical Company Limited · Industry
• Sex: Male
• Age: 20 Years – 50 Years
• Healthy volunteers: Accepted

Summary

The purposes of this study are to investigate the duration of P-glycoprotein inhibition after oral administration of HM30181AK tablet in healthy male subject and proper dose of HM30181AK tablet.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	HM30181AK 1mg	HM30181AK 1mg tablet
DRUG	HM30181AK 5mg	HM30181AK 5mg tablet
DRUG	HM30181AK 15mg	HM30181AK 15mg tablet
DRUG	HM30181AK 60mg	HM30181AK 60mg tablet
DRUG	Loperamide 2mg	Loperamide 2mg capsule

Timeline

• Start date: 2009-06-01
• Primary completion: 2009-08-01
• Completion: 2009-09-01
• First posted: 2009-08-07
• Last updated: 2010-09-13

Locations

1 site across 1 country: South Korea